|
(Health-NewsWire.Net, April 27, 2021 ) According to the new market research report dPCR and qPCR market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0% between 2020 and 2025.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
Factors such as the rising incidence of target infectious diseases and genetic disorders; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; technological advancements in PCR technologies and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use.
Based on application, the qPCR market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications. The clinical applications segment is estimated to dominate the qPCR applications market in 2020. The key factors driving the market growth of rising incidence of infectious and genetic diseases, clinical applications segment include the growing usage of qPCR in disease diagnosis, and growing public emphasis on early & effective disease diagnosis & treatment.
Based on products & services, the qPCR market is categorized into reagents and consumables, instruments and software & services. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life science research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples).
Based on end users, the qPCR market is segmented into research laboratories and academic institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, clinical research organizations (CROs), and forensic laboratories. In 2019, the hospitals and diagnostic centers segment accounted for the largest share of the market. This can be attributed to the ongoing expansion of healthcare infrastructure across emerging countries, high prevalence of target diseases, increasing market availability of qPCR reagents for clinical diagnostic applications and growing awareness among end users related to the benefits offered by qPCR for clinical diagnosis.
In 2020, North America is expected to dominate the qPCR and dPCR market, followed by Europe. The large share of the North American regional segment can be attributed to the availability of R&D funding for genomic research (coupled with the robust research infrastructure in the region), increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), expanding use of PCR techniques in clinical diagnostics & forensics, and early commercialization of qPCR/dPCR products compared to other regions.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204
The prominent players operating in the dPCR and qPCR market are Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
